The rate of intraductal papillary mucinous neoplasms of the pancreas (IPMNs) progression is much slower than that of invasive ductal adenocarcinomas. The identification of a clinicopathological marker to distinguish IPMNs from ductal adenocarcinomas is important for understanding the molecular mechanisms of pancreatic cancer.
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INTRODUCTION
Pancreatic adenocarcinomas are currently the fourth leading cause of cancer-related mortality. Almost all patients are expected to die from the disease due to the propensity of early metastasis, and because the disease is highly resistant to radiation and chemotherapy. Despite our increasing knowledge in tumor biology, the treatment efficacy of pancreatic adenocarcinomas has not significantly improved over the past decade. Histological evaluation of resected pancreatic adenocarcinomas has facilitated the morphologic classification of dysplastic lesions that represent the putative precursors of invasive carcinoma-pancreatic intraepithelial neoplasias (PanINs) and intraductal papillary mucinous neoplasms (IPMNs). PanINs encompass a spectrum of pancreatic ductal epithelial changes characterized by enhanced mucin production, graded nuclear atypia, and loss of cell polarity, giving rise to ductal adenocarcinomas that account for about ninety percent of pancreatic tumors. 1, 2 IPMNs constitute another class of noninvasive precursor lesions that are histologically distinct from, but related to, PanINs. 3 IPMNs are defined as a papillary growth of mucin-producing epithelium of pancreatic duct and produce radiographically identifiable ductal dilatation, which may predominantly involve the main pancreatic ducts ("main ductal type"), the secondary ducts ("branch ductal type"), or both ("mixed type"). 3, 4 The frequency of malignancy in the main ductal type is much higher than that in the branch ductal type. 5 Most IPMNs are slow growing and less aggressive compared with conventional, pancreatic ductal adenocarcinomas. Therefore, an important goal in understanding pancreatic cancer progression is to clarify the different molecular mechanisms underlying IPMNs and ductal adenocarcinomas.
Molecular genetic analysis has implicated several genes in the progression of pancreatic cancer including: K-ras, INK4A/ARF, and p53 as well as elements of the EGF, TGFβ, Notch, Hedgehog, and PI-3 kinase signaling pathways. 6-9 Several of these molecules are reported to have different expression levels between in IPMNs and PanINs/ductal adenocarcinomas. For example, SMAD4 levels are reported to decrease in more than 40% of ductal adenocarcinomas, but not IPMNs. [10] [11] [12] About 85% of PanIN-3s are reported to express MUC1, but IPMNs rarely do. 13 On the other hand, K-ras, p53 mutations, and Sonic hedgehog expression are observed in both PanINs and IPMNs. [14] [15] [16] . However, it remains unclear how these molecules play roles in the progression of the pancreatic cancer.
Recently we demonstrated that CD133 is a marker of putative pancreatic progenitor cells during embryogenesis. 17 CD133 is expressed on the apical membrane of ductal cells in the normal adult pancreas and in carcinoma cells on pancreatic ductal adenocarcinomas. 18 The subpopulation of the pancreatic ductal adenocarcinoma cells expressing both CD133 and CXCR4 is involved in tumor metastasis. 19 However, the precise expression of CD133 in IPMNs has not yet been elucidated.
In this study, we examined the expression pattern of CD133 in ductal adenocarcinomas and IPMNs. We confirmed that CD133 was expressed in centroacinar region and intra-lobular ductal cells in adult pancreas. During carcinogenesis, CD133 was expressed in carcinoma cells on ductal adenocarcinomas. In contrast, CD133 expression was not detected in mucin-producing epithelial cells or carcinoma cells on IPMNs. These results suggest that downregulation of CD133 expression may be a useful clinicopathological marker distinguishing IPMNs from ductal adenocarcinomas. 
MATERIALS AND METHODS
Immunohistochemistry.
Immunohistochemical staining to detect CD133 expression was done on 3-4 µm sections from formalin-fixed, paraffin-embedded tissues, placed on coated glass slides, and dried at room temperature for overnight. Sections were dewaxed in xylene, rehydrated according to standard procedures. For antigen retrieval, the tissue sections were boiled for 40 min in 1x Target Retrieval Solution (Dako, Carpinteria, CA). The samples were then cooled in 1x Target Retrieval Solution at room temperature for 20 min and rinsed with distilled water three times, followed by peroxidase block with 3% H 2 O 2 in methanol for 5 min. After rinse with distilled water twice, the samples were 
RESULTS
CD133 Expression in Adult Pancreas.
To explore the different expression pattern of CD133 between ductal adenocarcinomas and IPMNs, we first examined CD133 expression in the normal adult pancreas using the well-characterized anti-CD133 mAb. 18, 19, 21, 22 (Table 1) . These results indicate ductal adenocarcinoma cells express CD133.
CD133 Expression in IPMNs.
We then examined CD133 expression in human IPMNs. Based on imaging studies, including computed tomography and endoscopic retrograde cholangiopancreatography (ERCP), dilatation (diameter > 1 cm) of the main duct with dilatation of the secondary ducts suggested a mixed type of IPMN (Figs. 3A, B ). The patient ( Table 2 , the patient number 1) underwent partial pancreatectomy with second portion duodenectomy (Fig. 3C ). Macroscopic examination confirmed dilatation of the main duct and the secondary ducts (Figs. 3C, D) . The IPMN also had carcinoma in situ (Fig. 4C ). CD133 expression was not detected in either the columnar mucin-producing epithelial cells (Figs. 4A, B ) or in the carcinoma in situ on the IPMN (Figs. 4C, D) .
CD133 expression was not detected in invasive carcinoma cells on an IPMN ( Table 2, the patient number 10), either (Figs. 4E, F). We observed that CD133-expressing ductal cells connected directly to the columnar mucin-producing epithelial cells that did not express CD133 (Figs. 4H, I) . In control staining of the IPMN, the columnar mucin-producing epithelial cells, ductal cells and the carcinoma cells all expressed CK-19 ( Fig. 4G and data not shown).
IPMNs are subclassified into a gastric type, an intestinal type, a pancreatobiliary type, and an oncocytic type. 23 We subclassified 25 IPMN samples into 15 gastric type IPMNs, 8 intestinal type IPMNs, a pancreatobiliary type IPMN, and an oncocytic type IPMN, based on histological features and immunohistochemical reactivities with antibodies to specific types of mucin (MUCs) ( Table 3 ). Five of the 15 gastric types and 4 of the 8 intestinal types contained carcinoma in situ. Moreover, we observed 9 IPMNs, each of which contained invasive carcinoma cells, and tentatively classified them as invasive IPMNs in this study. We subclassified the 9 invasive IPMNs into 5 tubular carcinoma type IPMNs and 3 colloid carcinoma type IPMNs. There was an invasive IPMN containing both the two types. The lack of CD133 expression was observed in all the 34 IPMNs examined ( Fig. 5 and Table 3 ). Taken together, these results indicate that IPMNs do not express CD133.
DISCUSSION
In this study we found that CD133 was expressed in the centroacinar and terminal ductal cells in the normal pancreas as well as in ductal adenocarcinomas. In contrast, we found that CD133 was not expressed in IPMNs. These results suggest that the lack of CD133 expression can be used as a clinicopathological marker to distinguish IPMNs from ductal adenocarcinomas.
Our result that CD133 expression in the normal ductal cells follows a gradient with weaker intensity in larger ductal cells is consistent with the previous report. 18 In addition we found that mucin-producing epithelial cells in IPMNs that lacked CD133 were directly connected to CD133-expressing ductal cells. CK-19, an epithelial cell marker, 24 was observed in the columnar mucin-producing epithelial cells, and the carcinoma cells on IPMNs as well as in normal ductal cells. These results allow us to provide at least three possibilities: (1) larger ductal cells (main pancreatic and inter-lobular ductal cells) or some specific epithelium among pancreatic duct which do not express CD133 might trans-differentiate to mucin-producing hyperplasia in IPMNs, followed by an adenoma-dysplasia-carcinoma sequence; (2) smaller ductal cells (terminal and intra-lobular ductal cells) might down regulate CD133 expression resulting in a trans-differentiation to mucin-producing epithelium in IPMNs; and (3) IPMNs might be derived from extra-ductal tissue, including exocrine or endocrine cells, which do not express CD133, and acquire an epithelial character(s). Further investigations will be required to resolve these possibilities.
PanINs have pancreatic ductal epithelial changes characterized by enhanced mucin production, graded nuclear atypia, and loss of cell polarity, giving rise to ductal adenocarcinoma. 1-3 Surprisingly we could not observe CD133 staining in PanIN-1As and -1Bs, PanIN-2s, or PanIN-3s (data not shown). We assume that larger ductal cells that do not express CD133 might trans-differentiate to mucin-producing hyperplasia in PanINs and that CD133 is not a marker distinguishing IPMNs from PanINs.
Metaplasia (the widespread inter-conversion of one cell type into another) has been associated with pancreatic cancer in both humans and animal models and a metaplasia-ductal adenocarcinoma sequence has been proposed for carcinogenesis in pancreas. 7, 9, 25, 26 Acinar-to-ductal metaplasia has been generally regarded as a transdifferentiation and premalignant state. [26] [27] [28] [29] Centroacinar cells have been reported to be involved in the metaplasia-ductal adenocarcinoma sequence. 7, 9 Here we demonstrated that not only centroacinar cells but also the ductal metaplasia of the acinar cells located in the border zone of ductal adenocarcinomas expressed CD133. Although it remains unknown if the ductal metaplasia of acinar cells is consistent with premalignant acinar-to-ductal metaplasia, our results suggest that CD133 may be one of the molecules involved in this process. In contrast, IPMNs did not express CD133, suggesting that the adenoma-dysplasia-carcinoma sequence in IPMNs may be different from the metaplasia-ductal adenocarcinoma sequence.
CD133 is considered as a universal marker of tissue-specific stem cells or tumor-initiating cells. We and other groups have demonstrated that CD133 is a marker of putative pancreatic progenitor cells. 17, 30 A recent report has described that CD133 is not restricted to stem cells or tumor initiating cells in adult pancreas and that CD133-expressing cells in the pancreas include at least two subpopulations: 1) a main population expressing CD133 at the cell surface which represents a particular stage in cell differentiation connected to the formation of lumina and ducts and 2) a minor cell population that predominantly exhibits cytoplasmic CD133 staining, which represents less than 1% of epithelia cells, both in normal pancreas and in ductal adenocarcinomas. 18 We have also observed cytoplasmic CD133 staining in a minor population of ductal adenocarcinomas cells (Fig. 2-2) . The functional significance of this cytoplasmic staining remains unclear. We demonstrated that CD133 staining was observed in all of the ductal adenocarcinomas examined in this study, however the CD133 staining was not observed in all of the ductal adenocarcinoma cells ( Table 1 ).
The reason for this is not known, but one possibility is that the microenvironment around ductal adenocarcinoma cells might affect CD133 expression level and/or subcellular localization. Further studies are necessary to clarify the function of CD133 in pancreatic ductal adenocarcinomas. Original magnification was 400x. 
